The role of PPAR-γ in macrophage differentiation and cholesterol uptake (original) (raw)

• Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A. & Evans, R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771–774 (1992).
  Article CAS Google Scholar
• Kliewer, S.A., Umesono, K., Mangelsdorf, D.J. & Evans, R.M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355, 446–449 (1992).
  Article CAS Google Scholar
• Spiegelman, B.M. Peroxisome proliferator-activated receptor γ: A key regulator of adipogenesis and systemic insulin sensitivity. Eur. J. Med. Res. 2, 457–464 (1997).
  CAS PubMed Google Scholar
• Law, R.E. et al. Expression and function of PPAR-γ in rat and human vascular smooth muscle cells. Circulation 101, 1311–1318 (2000).
  Article CAS Google Scholar
• Clark, R.B. et al. The nuclear receptor PPAR-γ and immunoregulation: PPAR-γ mediates inhibition of helper T cell responses. J. Immunol. 164, 1364–1371 (2000).
  Article CAS Google Scholar
• Forman, B.M. et al. 15-Deoxy-Δ12,14prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-γ. Cell 83, 803–812 (1995).
  Article CAS Google Scholar
• Lehmann, J.M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J. Biol. Chem. 270, 12953–12956 (1995).
  Article CAS Google Scholar
• Kliewer, S.A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 94, 4318–4323 (1997).
  Article CAS Google Scholar
• Tontonoz, P., Nagy, L., Alvarez, J.G.A., Thomazy, V.A. & Evans, R. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241–252 (1998).
  Article CAS Google Scholar
• Nagy, L., Tontonoz, P., Alvarez, J.G.A., Chen, H. & Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ. Cell 93, 229–240 (1998).
  Article CAS Google Scholar
• Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79–82 (1998).
  Article CAS Google Scholar
• Jiang, C., Ting, A.T. & Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86 (1998).
  Article CAS Google Scholar
• Marx, N., Sukhova, G., Murphy, C., Libby, P. & Plutzky, J. Macrophages in human atheroma contain PPAR-γ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPAR-γ) expression and reduction of MMP-9 activity through PPAR-γ activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153, 17–23 (1998).
  Article CAS Google Scholar
• Ricote, M. et al. Expression of the peroxisome proliferator-activated receptor γ (PPAR-γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoproteins. Proc. Natl. Acad. Sci. USA 95, 7614–7619 (1998).
  Article CAS Google Scholar
• Chinetti, G. et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101, 2411–2417 (2000).
  Article CAS Google Scholar
• Kersten, S., Desvergne, B. & Wahli, W. Roles of PPARs in health and disease. Nature 405, 421–424 (2000).
  Article CAS Google Scholar
• Willoughby, D.A., Moore, A.R. & Colville-Nash, P.R. Cyclopentenone prostaglandins—new allies in the war on inflammation [news]. Nature Med. 6, 137–138 (2000).
  Article CAS Google Scholar
• Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103–108 (2000).
  Article CAS Google Scholar
• Straus, D.S. et al. 15-Deoxy-Δ12,14prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway [In Process Citation]. Proc. Natl. Acad. Sci. US A 97, 4844–4849 (2000).
  Article CAS Google Scholar
• Vaidya, S., Somers, E.P., Wright, S.D., Detmers, P.A. & Bansal, V.S. 15-Deoxy-Δ12,14prostaglandin J2 inhibits the β-2 integrin-dependent oxidative burst: involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation. J. Immunol. 163, 6187–6192 (1999).
  CAS PubMed Google Scholar
• Pasceri, V., Wu, H.D., Willerson, J.T. & Yeh, E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101, 235–238 (2000).
  Article CAS Google Scholar
• Spiegelman, B.M. PPAR-γ in monocytes: less pain, any gain? Cell 93, 153–155 (1998).
  Article CAS Google Scholar
• Barak, Y. et al. PPAR-γ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585–595 (1999).
  Article CAS Google Scholar
• Rosen, E.D. et al. PPAR-γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611–617 (1999).
  Article CAS Google Scholar
• Kubota, N. et al. PPAR-γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597–609 (1999).
  Article CAS Google Scholar
• Moore, K.J., Fabunmi, R.P., Andersson, L.P. & Freeman, M.W. _In vitro_-differentiated embryonic stem cell macrophages: a model system for studying atherosclerosis-associated macrophage functions. Arterio. Thromb. Vasc. Biol. 18, 1647–1654 (1998).
  Article CAS Google Scholar
• Thieringer, R. et al. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo. J. Immunol. 164, 1046–1054 (2000).
  Article CAS Google Scholar
• Huang, J.T. et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378–382 (1999).
  Article CAS Google Scholar
• Feng, J. et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-γ. J. Lipid Res. 41, 688–696 (2000).
  CAS PubMed Google Scholar
• de Villiers, W.J., Fraser, I.P., Hughes, D.A., Doyle, A.G. & Gordon, S. Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function. J. Exp. Med. 180, 705–709 (1994).
  Article CAS Google Scholar
• Armesilla, A.L., Calvo, D. & Vega, M.A. Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. J. Biol. Chem. 271, 7781–7787 (1996).
  Article CAS Google Scholar
• Febbraio, M. et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274, 19055–19062 (1999).
  Article CAS Google Scholar
• Febbraio, M. et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105, 1049–1056 (2000).
  Article CAS Google Scholar
• Calvo, D., Gomez-Coronado, D., Suarez, Y., Lasuncion, M.A. & Vega, M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res. 39, 777–788 (1998).
  CAS PubMed Google Scholar
• Huh, H.Y., Pearce, S.F., Yesner, L.M., Schindler, J.L. & Silverstein, R.L. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 87, 2020–2028 (1996).
  CAS PubMed Google Scholar
• Repa, J.J. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers [see comments]. Science 289, 1524–1529 (2000).
  Article CAS Google Scholar
• Li, A.C. et al. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106, 523–531 (2000).
  Article CAS Google Scholar
• Ghazzi, M.N. et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46, 433–439 (1997).
  Article CAS Google Scholar
• Noguchi, N. et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 123, 227–234 (1996).
  Article CAS Google Scholar
• Minamikawa, J., Yamauchi, M., Inoue, D. & Koshiyama, H. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus [letter; comment]. J. Clin. Endocrinol. Metab. 83, 1041–1042 (1998).
  Article CAS Google Scholar
• Law, R.E. et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98, 1897–1905 (1996).
  Article CAS Google Scholar
• Shinohara, E. et al. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 136, 275–279 (1998).
  Article CAS Google Scholar
• Freeman, M. et al. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc. Natl. Acad. Sci. USA 87, 8810–8814 (1990).
  Article CAS Google Scholar
• Milstone, D.S., Bradwin, G. & Mortensen, R.M. Simultaneous Cre catalyzed recombination of two alleles to restore neomycin sensitivity and facilitate homozygous mutations. Nucleic Acids Res. 27, 10 (1999).
  Article Google Scholar
• Lindblad-Toh, K. et al. Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nature Genet. 24, 381–386 (2000).
  Article CAS Google Scholar
• Jacobs, N.L. et al. Analysis of a Chinese hamster ovary cell mutant with defective mobilization of cholesterol from the plasma membrane to the endoplasmic reticulum. J. Lipid Res. 38, 1973–1987 (1997).
  CAS PubMed Google Scholar
• Ashkenas, J. et al. Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors. J. Lipid. Res. 34, 983–1000 (1993).
  CAS PubMed Google Scholar